cadenttx.comHealthcareFounded: 2010Funding to Date: $67.4MM
Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.
View Enterprise Value for Cadent Therapeutics.
